Pectin
Based on 1 Customer Validation
Pectin is a heteropolysaccharide, derived from the cell wall of higher plants. Pectin involves in the formation of nanoparticles as a delivery vehicle of agents. Pectin is also an adsorbent, a broad-spectrum antimicrobial agent that binds to bacteria toxins and other irritants in the intestinal mucosa, relieves irritated mucosa.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- Assay : 88.9%
- CAS 番号: 9000-69-5
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
生物活性
製品説明
IC50 & Target
|
Human Endogenous Metabolite |
体外実験
Pectin (5 mg/mL; 24, 48, and 72 h) shows low cytotoxicity on HepG2 cells, and can be made into nanoparticles (PPN), encapsulating Paclitaxel (HY-B0015), decreases the Paclitaxel cytotoxicity (%) from 55.6% to 21.7% at 72 h[1].
Pectin (3, 6 mg/mL; 48 h) inhibits Staphylococcus aureus ATCC 25923 growth, with a minimum inhibitory concentration (MIC) of 40 mg/mL[2].
Pectin inhibits Gram-negative Helicobacter pylori, a common human pathogen, shows highest antibacterial activity at pH 5.0, with a minimum inhibitory concentration (MIC) of 0.162 mg/mL and minimum bactericidal concentration (MBC) of 0.325 mg/mL[2].
Pectin displays lower antibacterial activity against E. coli with MICs of 25 mg/mL and 50 mg/mL and MBC values ranging between 25-50 mg/mL[2].
Pectin exhibits the antibacterial activity via its undissociated acid form[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 9000-69-5
-
性状 Solid
-
Color Off-white to light yellow
-
SMILES
[Pectin]
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
純度とドキュメンテーション
-
データシート (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Verma AK, et al. Pharmacokinetics and biodistribution of negatively charged pectin nanoparticles encapsulating paclitaxel. Cancer Nanotechnol. 2013;4(4-5):99-102. [Content Brief]
[2]. Ciriminna R, et al. Pectin: A Long-Neglected Broad-Spectrum Antibacterial. ChemMedChem. 2020 Dec 3;15(23):2228-2235. [Content Brief]
[3]. Wikiera A, et al. Prozdrowotne właściwości pektyn [Health-promoting properties of pectin]. Postepy Hig Med Dosw (Online). 2014 Jan 2;68:590-6. Polish. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)